Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer-Reference-Cited by-同舟云学术

Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer

Published:2023-08-27 Issue:17 Volume:15 Page:4290
ISSN:2072-6694
Container-title:Cancers
language:en
Short-container-title:Cancers

Author:

Petranović Ovčariček Petra¹²^ORCID,Campenni Alfredo³,de Keizer Bart⁴^ORCID,Deandreis Desiree⁵,Kreissl Michael C.⁶^ORCID,Vrachimis Alexis⁷^ORCID,Tuncel Murat⁸^ORCID,Giovanella Luca⁹¹⁰^ORCID

Affiliation:

1. Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, 10000 Zagreb, Croatia

2. School of Medicine, University of Zagreb, 10000 Zagreb, Croatia

3. Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, 98100 Messina, Italy

4. Department of Nuclear Medicine and Radiology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands

5. Institute Gustave Roussy, 94800 Villejuif, France

6. Division of Nuclear Medicine, Department of Radiology and Nuclear Medicine, University Hospital Magdeburg, Otto-von-Guericke University, 39120 Magdeburg, Germany

7. Department of Nuclear Medicine, German Oncology Center, University Hospital of the European University, Limassol 4108, Cyprus

8. Department of Nuclear Medicine, Hacettepe University, Ankara 06230, Turkey

9. Clinic for Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland

10. Clinic for Nuclear Medicine, University Hospital of Zürich, 8004 Zürich, Switzerland

Abstract

Differentiated thyroid cancer (DTC) is the most common subtype of thyroid cancer and has an excellent overall prognosis. However, metastatic DTC in certain cases may have a poor prognosis as it becomes radioiodine-refractory. Molecular imaging is essential for disease evaluation and further management. The most commonly used tracers are [18F]FDG and isotopes of radioiodine. Several other radiopharmaceuticals may be used as well, with different diagnostic performances. This review article aims to summarize radiopharmaceuticals used in patients with radioiodine-refractory DTC (RAI-R DTC), focusing on their different molecular pathways. Additionally, it will demonstrate possible applications of the theranostics approach to this subgroup of metastatic DTC.

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Link

https://www.mdpi.com/2072-6694/15/17/4290/pdf

Reference70 articles.

1. Giovanella, L., Deandreis, D., Vrachimis, A., Campenni, A., and Ovcaricek, P.P. (2022). Molecular Imaging and Theragnostics of Thyroid Cancers. Cancers, 14.

2. Definition and Management of Radioactive Iodine-Refractory Differentiated Thyroid Cancer;Schlumberger;Lancet Diabetes Endocrinol.,2014

3. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer;Haugen;Thyroid,2016

4. Integrated Genomic Characterization of Papillary Thyroid Carcinoma;Agrawal;Cell,2014

5. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013;Lim;JAMA,2017